<DOC>
	<DOCNO>NCT02438683</DOCNO>
	<brief_summary>This trial conduct evaluate , control setting , potential cardiac effect anticipate therapeutic supra-therapeutic dose BI 409306 rest exercise condition . Since drug develop part disease expectedly high number elderly ( AD ) , characterization cardiac safety BI 409306 consider important development compound . This trial conduct evaluate , control setting , potential cardiac effect anticipate therapeutic supra-therapeutic dose BI 409306 rest exercise condition . Since drug develop part disease expectedly high number elderly ( AD ) , characterization cardiac safety BI 409306 consider important development compound .</brief_summary>
	<brief_title>BI 409306 Cardiac Safety Trial Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test . Age 18 45 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Waisttoheight ratio le 0.5 Signed date write informed consent prior admission study accordance GCP local legislation Ready able use highly effective method birth control result low failure rate le 1 % per year use consistently correctly . A list contraception method meet criterion provide subject information . Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement Systolic blood pressure le 90 mm Hg than140 mmHg Diastolic blood pressure le 50 mm Hg 90 mmHg Pulse rate le 45 bpm 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere PK trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc interval Participation another trial investigational drug administer within 60 day prior plan administration trial medication Smoker ( unless subject quit smoking least 30 day prior screen ) Alcohol abuse ( consumption 30 g per day ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalaemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study Any suicidal ideation type 2 5 CSSRS past 12 month ( i.e . active suicidal thought , active suicidal think method , active suicidal think intent without specific plan , active suicidal think plan intent ) Any lifetime history suicidal behaviour ( i.e . actual attempt , interrupt attempt , abort attempt , preparatory act behaviour ) . In addition , follow trialspecific exclusion criterion apply : CYP2C19 PM ( treatment allocation ) History macular degeneration Beard unwillingness shave trial ( facilitate appropriate measurement CPX require wear face mask ) Physical disability precludes safe adequate CPX investigation Known latex allergy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>